Precision Medicine in Oncology

Coverage of clinical trial results presented across a range of solid tumor cancers, including breast, ovarian, colorectal, and non-small cell lung cancer, among other types; as well as important findings in genomic testing.

The therapy is designed to target multiple receptors and could address an unmet need in metastatic colorectal cancer.

Coverage from the American College of Cardiology Scientific Session Together With World Congress of Cardiology, held March 4-6, 2023, in New Orleans, Louisiana.

Miruna Sasu, PhD, MBA, became president and CEO of COTA Healthcare in March 2022, not quite a year after joining the company as its chief strategy officer. As the importance of RWD grows, Sasu is ready to take its use in precision oncology to new levels. She spoke with Evidence-Based Oncology™ (EBO) about her new role.

Development of FGFR inhibitors, which target fibroblast growth factor receptors, is among the most important advances in the treatment of cholangiocarcinoma.

This new study, conducted among individuals receiving treatment at Cancer Center of Kansas, investigated the potential benefits of incorporating liquid biopsy into community-based oncology practices.

A new retrospective study of patients with high-risk t(8;21) acute myeloid leukemia (AML) investigated outcomes from 2 therapies following return of minimal residual disease–positive status after allogeneic hematopoietic stem cell transplantation.

This new study explores the utility and potential of noninvasive liquid biopsies as a method of early detection in lung cancer.

This new study synthesized data from 5 clinical trials at the University of California, San Francisco, to evaluate the utility of minimal residual disease (MRD) and serum-free light chain (SFLC) levels in predicting progression-free survival among patients with multiple myeloma (MM) receiving chimeric antigen receptor T-cell therapies.

Circulating tumor DNA (ctDNA) as a detection method for renal cell carcinoma (RCC) was investigated in a new review that summarizes evidence on ctDNA use and potential.

Despite being the most common pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) is notoriously difficult to treat, while new research shows treatment and diagnosis could benefit from minimally invasive liquid-based biopsy.

Interim data from a National Cancer Institute Center for Cancer Research study show demonstrated immune reactions in patients with breast cancer following immunotherapy with their own tumor-infiltrating lymphocytes (TIL).

This 9-month investigation looked into the potential for next-generation sequencing (NGS) at the point of care to increase turnaround time for biomarker testing results in advanced colorectal cancer (CRC).

In this poster presented at the 2022 ASCO Gastrointestinal Cancers Symposium, minimal residual disease (MRD) status as detected by postsurgery plasma cell-free DNA continued its strong track record of being a reliable predictor of disease progression in colorectal cancer (CRC).

An abstract presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition assessed real-world data on patients with multiple myeloma to provide insight into longitudinal testing patterns and rates of sustained minimal residual disease (MRD) negativity.

An abstract presented at the 63rd American Society of Hematology Meeting & Exposition found that the regimen was effective and that MRD could potentially be used as a biomarker to inform treatment duration.

A new review explored using partial tandem duplication levels from the MLL gene to monitor for minimal residual disease (MRD) status to predict disease relapse following allogeneic hematopoietic stem cell transplant.

Recent learnings about treating parenchymal brain metastases stem from several solid tumors, most commonly non-small cell lung cancer, breast cancer, and melanoma, all of which have benefitted from targeted treatments in recent years.

Minimal residual disease (MRD) can predict which patients with classical Hodgkin lymphoma (HL) will relapse after autologous stem cell transplantation (ASCT).